Maral Zhumabekova

Dr. Maral Zhumabekova


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
VKViktoriya Keyer
Viktoriya Keyer
AKAitolkyn Kydyrbayeva
Aitolkyn Kydyrbayeva
TKTolganay Kulatay
Tolganay Kulatay
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
DBDmitrii Bazhenov
Dmitrii Bazhenov
ASAlexandr V. Shustov
Alexandr V. Shustov
CAR-T cell therapy represents a breakthrough in cancer treatment, yet its implementation in developing countries remains challenging due to technical and infrastructural barriers. This study aimed to establish clinical-scale CAR-T production in Kazakhstan, a country with no prior experience in advanced cell and gene therapies. We implemented a complete CAR-T manufacturing pipeline, including in-house lentiviral vector (LV) production and automated CAR-T cell processing using the CliniMACS Prodigy system. Two anti-CD19 CAR LVs were used, one modeled after FDA-approved Kymriah (4-1BB costimulation) and another replicating Yescarta (CD28 costimulation). The vector produced locally achieved functional titers of 1.5 × 1010 TU/mL after concentration. Twelve clinical-scale CAR-T products were manufactured, exhibiting a memory-skewed T-cell phenotype. Functional assessments revealed that CD28-based CAR-T cells produced significantly higher Th1 cytokines (IFN-γ, TNF-α, IL-2; p < 0.05) than 4-1BB-based cells, though both demonstrated comparable cytotoxicity against CD19+ targets. These findings demonstrate the feasibility of establishing CAR-T production in resource-limited settings using a decentralized manufacturing framework. This work provides a scalable model of CAR-T therapy production in developing regions, suitable for clinical implementation using the hospital exemption framework. Critical gaps in access to advanced immunotherapies, including CAR-T, in the Central Eurasia region are addressed.

13 February 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
TKTolganay Kulatay
Tolganay Kulatay
BIBakytkali Ingirbay
Bakytkali Ingirbay
ZSZhanar Shakhmanova
Zhanar Shakhmanova
VKViktoriya Keyer
Viktoriya Keyer
ASAlexandr V. Shustov
Alexandr V. Shustov
Transient gene expression (TGE) is commonly employed for protein production, but its reliance on plasmid transfection makes it challenging to scale up. In this paper, an alternative TGE method is presented, utilizing pseudoinfectious alphavirus as an expression vector. Pseudoinfectious viruses (PIV) and a replicable helper construct were derived from the genome of the Venezuelan equine encephalitis virus. The PIV carries a mutant capsid protein that prevents packaging into infectious particles, while the replicable helper encodes a wild-type capsid protein but lacks other viral structural proteins. Although PIV and the helper cannot independently spread infection, their combination results in increased titers in cell cultures, enabling easier scale-up of producing cultures. The PIV-driven production of a model protein outperforms that of alphavirus replicon vectors or simple plasmid vectors. Another described feature of the expression system is the modification to immobilized metal affinity chromatography (IMAC), allowing purification of His-tagged recombinant proteins from a conditioned medium in the presence of substances that can strip metal from the IMAC columns. The PIV-based expression system allows for the production of milligram quantities of recombinant proteins in static cultures, without the need for complex equipment such as bioreactors, and complies with regulatory requirements due to its distinction from common recombinant viruses.

20 August 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
GNGaziza Nigmatulla
Gaziza Nigmatulla
AKAitolkyn Kydyrbayeva
Aitolkyn Kydyrbayeva
TKTolganay Kulatay
Tolganay Kulatay
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
BIBakytkali Ingirbay
Bakytkali Ingirbay
ASAlexandr V. Shustov
Alexandr V. Shustov
The growing demand for high-quality plasmid DNA (pDNA) in cell and gene therapy, including chimeric antigen receptor T-cell therapy (CAR-T) manufacturing, is constrained by the limited availability of transfection-grade plasmids. This study describes a practical, scalable, and cost-effective acidic phenol extraction method based on a modified alkaline lysis protocol. This approach efficiently removes endotoxins and residual genomic DNA without requiring chromatography or ultracentrifugation. When benchmarked against CsCl density gradient ultracentrifugation and a commercial midiprep kit, the acidic phenol method delivered comparable plasmid purity and functional performance while providing superior scalability, yielding 5–10 mg of pDNA per 500 mL culture. Notably, residual endotoxin levels were negligible for downstream applications such as transfection and lentiviral vector packaging. Lentiviral vectors produced with these plasmids reached titers exceeding 5 × 106 TU/mL, with transduction efficiencies statistically indistinguishable from those obtained with CsCl-purified DNA. The acidic phenol extraction method is a robust, scalable, and cost-effective alternative to industry-standard methods, matching them in yield and purity while being readily scalable, making it a practical tool for both academic research and preparative laboratory production.

23 October 2026 in Astana Medical Journal
Verified
Journal Article
Closed access
ИМИван Мишутин
Иван Мишутин
VKVadim Kemaykin
Vadim Kemaykin
AKAzat Karabekov
Azat Karabekov
AKAleksandr Kolesnev
Aleksandr Kolesnev
FSFariza Shokubayeva
Fariza Shokubayeva
ZBZhandos Burkitbayev
Zhandos Burkitbayev
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies but can cause rapidly progressive inflammatory, neurologic, infectious, hematologic, cardiovascular, respiratory, and renal complications with overlapping clinical manifestations. This review aimed to synthesize current evidence on their early diagnosis, monitoring, critical care, and interdisciplinary management. A targeted narrative search was conducted in PubMed, including MEDLINE-indexed records, Google Scholar, and websites of international professional societies; the last search was performed on 30 September 2026. The structured PubMed strategy retrieved 4,178 records. Publications from January 2016 through September 2026 were considered, together with two earlier foundational guidelines on febrile neutropenia and acute kidney injury. Thirty-five sources were included after title/abstract screening and targeted full-text assessment. The review addresses cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infection and sepsis, acute organ dysfunction, prolonged cytopenias, and secondary immunodeficiency. Standardized toxicity grading, serial neurologic assessment, and continuous evaluation of hemodynamics, oxygenation, fluid balance, renal function, coagulation, ferritin, fibrinogen, blood cell counts, and microbiological findings are central to early recognition of deterioration. Fever and organ dysfunction require simultaneous evaluation for immune-mediated toxicity and infection because these conditions may coexist and no single biomarker reliably excludes sepsis. Management should combine syndrome-directed anti-inflammatory treatment, prompt empirical antimicrobial therapy when indicated, and timely organ support. Advanced support outside the intensive care unit is an organizational exception rather than an evidence-proven equivalent model and must not delay transfer. Predefined escalation pathways and coordinated multidisciplinary care are essential for safe implementation of CAR T-cell therapy. Keywords: receptors, chimeric antigen, immunotherapy, adoptive, cytokine release syndrome, neurotoxicity syndromes, critical care, sepsis, patient care team.

24 January 2026 in Biology
Verified
Journal Article
Open access
PDF file
PTPavel Tarlykov
Pavel Tarlykov
BIBakytkali Ingirbay
Bakytkali Ingirbay
DADana Auganova
Dana Auganova
TKTolganay Kulatay
Tolganay Kulatay
VKViktoriya Keyer
Viktoriya Keyer
ASAlexandr V. Shustov
Alexandr V. Shustov
The flavivirus NS1 protein is a component of the viral replication complex and plays diverse, yet poorly understood, roles in the viral life cycle. To enable real-time visualization of the developing replication organelle and biochemical analysis of tagged NS1 and its interacting partners, we engineered a replication-competent yellow fever virus (YFV) replicon encoding a C-terminal fusion of NS1 with green fluorescent protein (NS1-GFP). The initial variant was non-viable in the absence of trans-complementation with wild-type NS1; however, viability was partially restored through the introduction of co-adaptive mutations in GFP (Q204R/A206V) and NS4A (M108L). Subsequent cell culture adaptation generated a 17-nucleotide frameshift within the NS1-GFP linker, resulting in a more flexible and less hydrophobic linker sequence. The optimized genome, in the form of a replicon, replicates in packaging cells that produce YFV structural proteins, as well as in naive BHK-21 cells. In the packaging cells, the adapted NS1-GFP replicon produces titers of infectious particles of approximately 106 FFU/mL and is genetically stable over five passages. The expressed NS1-GFP fusion protein localizes to the endoplasmic reticulum and co-fractionates with detergent-resistant heavy membranes, a hallmark of flavivirus replication organelles. This NS1-GFP replicon provides a novel platform for studying NS1 functions and can be further adapted for proximity-labeling strategies aimed at identifying the still-unknown protease responsible for NS1-NS2A cleavage.

28 May 2026 in Biology
Verified
Journal Article
Open access
PDF file
AKAitolkyn Kydyrbayeva
Aitolkyn Kydyrbayeva
VKViktoriya Keyer
Viktoriya Keyer
TKTolganay Kulatay
Tolganay Kulatay
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
BIBakytkali Ingirbay
Bakytkali Ingirbay
ASAlexandr V. Shustov
Alexandr V. Shustov
Lentiviral vectors (LVs) are indispensable tools in cell and gene therapy. Rising demand has created a global shortage of LVs, driving the development of novel packaging approaches. We report a novel vector packaging approach using autonomously replicating cytoplasmic RNAs (replicons) to express packaging proteins. Yellow fever virus (YFV) was used as a source of replicons encoding the HIV-1 Gag–Pol polyprotein together with reporter or selectable markers. YFV replicons were able to establish chronic infection in HEK293FT cells. Replicons expressing HIV-1 Gag–Pol containing the wild-type HIV-1 protease caused strong cytotoxicity, which prevented the selection of polyclonal cell pools harboring the replicon. In contrast, a replicon carrying the T26S mutation in the HIV-1 protease gene showed no measurable cytotoxic effects, enabling the generation of stable replicon-containing cell pools. The replicon cell pools were established using antibiotic selection and maintained Gag-Pol expression for at least ten passages under selection pressure. Using these first-generation replicon cell pools as packaging cells, LV production required only transient transfection of a transfer vector, a Tat/Rev plasmid, and an envelope plasmid. Yields reached ~106 TU/mL prior to concentration and ~109 TU from multilayer cell stacks, which fall within the range typically reported for conventional transient transfection systems under similar culture conditions. The resulting vectors efficiently transduced target cells, and no replication-competent lentivirus (RCL) was detected using a two-phase RCL assay with p24 ELISA detection. This demonstrator platform utilizing replicon cell pools represents a novel approach for LV packaging.